United Therapeutics Corporation
UTHR
$301.04
-$1.38-0.46%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 17.62% | 19.85% | 23.63% | 25.04% | 23.96% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.62% | 19.85% | 23.63% | 25.04% | 23.96% |
| Cost of Revenue | 16.21% | 18.41% | 20.27% | 24.26% | 37.38% |
| Gross Profit | 17.80% | 20.03% | 24.04% | 25.14% | 22.46% |
| SG&A Expenses | 20.72% | 24.95% | 34.54% | 21.73% | 23.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.39% | 22.65% | 25.37% | 28.87% | 33.38% |
| Operating Income | 20.01% | 17.08% | 21.95% | 21.26% | 15.26% |
| Income Before Tax | 15.41% | 13.24% | 20.77% | 24.20% | 25.28% |
| Income Tax Expenses | 13.02% | 6.87% | 18.79% | 26.79% | 34.35% |
| Earnings from Continuing Operations | 16.15% | 15.25% | 21.35% | 23.46% | 22.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.15% | 15.25% | 21.35% | 23.46% | 22.71% |
| EBIT | 20.01% | 17.08% | 21.95% | 21.26% | 15.26% |
| EBITDA | 20.53% | 18.08% | 22.56% | 21.48% | 15.30% |
| EPS Basic | 19.89% | 21.16% | 25.66% | 25.97% | 22.46% |
| Normalized Basic EPS | 27.46% | 27.05% | 31.44% | 34.34% | 26.52% |
| EPS Diluted | 17.75% | 18.50% | 24.01% | 25.37% | 22.99% |
| Normalized Diluted EPS | 25.07% | 24.22% | 29.63% | 33.61% | 27.14% |
| Average Basic Shares Outstanding | -3.24% | -4.90% | -3.42% | -1.56% | 0.43% |
| Average Diluted Shares Outstanding | -1.37% | -2.77% | -2.17% | -1.41% | -0.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |